September 28, 2018 - Posts

Whistleblower Roundup – September 28, 2018

A look back at the week’s news and developments affecting whistleblowers.


SEC Announces $4 Million Award to Foreign Whistleblower 

The U.S. Securities and Exchange Commission (SEC) has awarded an anonymous foreign whistleblower, who had come forward with information leading to an enforcement action with a regulatory bounty. The tipster is getting $4 million but few details were available regarding the nature of the underlying facts or enforcement action or the identity of the whistleblower. The announcement brings the whistleblower program’s total endowment to over $326 million since issuing its first award in 2012. SEC enforcement actions from tip-offs have resulted in nearly $1.7 billion in fines since the program’s inception in 2011.


Whistleblower Recovers More Than $6.6 Million in False Claims Act

East Alabama Medical Center (EAMC) and its subsidiary Aperian Laboratory Solutions, LLC agreed to pay $4,250,000, plus attorney’s fees and litigation expenses, to settle claims they violated the Anti-Kickback Statute and the False Claims Act by submitting false payments to Medicare. This settlement was in addition to earlier settlements in this same case of nearly $2.4 million. The whistleblower suit alleged Aperian paid percentage commission kickbacks to Summit Diagnostics and Compass Laboratory Solutions, marketing companies that arranged for doctors nationwide to refer toxicology lab tests to Aperian in Alabama. To read more click here.


Eye Doctor to Pay $7 Million Settlement in Fraud Case

A Garden City ophthalmologist will pay nearly $7 million to settle civil fraud claims that he used unapproved drugs purchased overseas on patients and then sought reimbursement by Medicare, the Department of Justice announced Monday. “Dr. Fleckner bypassed the FDA’s regulatory authority by purchasing and administering unapproved pharmaceutical products in violation of Medicare regulations,” Richard Donoghue, U.S. attorney for the Eastern District of New York, said. “The settlement holds Dr. Fleckner accountable for his actions and ensures that Medicare funds will only be used for FDA-approved pharmaceuticals.”


To learn more about our Whistleblower & Qui Tam practice click here. Our firm is located in Nashville, Tennessee but we represent whistleblowers all around the country. Call us today at (615) 244 2202.

Get in touch

Contact us today for a free consultation. We are here to work for you!